Table 6. Effect of patient age on clinical outcomes.
| Outcome | DOAC cohort and patient age | |||||
|---|---|---|---|---|---|---|
| Apixaban | Dabigatran etexilate | Rivaroxaban | ||||
| Age < 75 y ( n = 675) |
Age ≥ 75 y ( n = 582) |
Age < 75 y ( n = 374) |
Age ≥ 75 y ( n = 294) |
Age < 75 y ( n = 618) |
Age ≥ 75 y ( n = 464) |
|
| Major bleeding | ||||||
| No. % (95% CI) |
6,
0.89
(0.41–1.93) |
11,
1.89
(1.06–3.35) |
3,
0.80
(0.27–2.33) |
3,
1.02
(0.35–2.96) |
11,
1.78
(1–3.16) |
9,
1.94
(1.02–3.64) |
| p -Value | p = 0.15 | p = 1.0 | p = 1.0 | |||
| Arterial thromboembolism | ||||||
| No. % (95% CI) |
1,
0.15
(0.03–0.83) |
1,
0.17
(0.03–0.97) |
2,
0.53
(0.15–1.93) |
2,
0.68
(0.19–2.45) |
3,
0.49
(0.17–1.42) |
1,
0.22
(0.04–1.21) |
| p -Value | p = 1.0 | p = 1.0 | p = 0.64 | |||
| Any bleed (MB + CRNMB) | ||||||
| No. % (95% CI) |
15,
2.22
(1.35–3.63) |
23,
3.95
(2.65–5.86) |
12,
3.21
(1.84–5.52) |
7,
2.38
(1.16–4.83) |
23,
3.72
(2.49–5.52) |
22,
4.74
(3.15–7.07) |
| p- Value | p = 0.10 | p = 0.64 | p = 0.44 | |||
| Any thromboembolism | ||||||
| No. % (95% CI) |
6,
0.89
(0.41–1.93) |
3,
0.52
(0.18–1.5) |
3,
0.80
(0.27–2.33) |
4,
1.36
(0.53–3.45) |
4,
0.65
(0.25–1.65) |
1,
0.22
(0.04–1.21) |
| p -Value | p = 0.52 | p = 0.71 | p = 0.40 | |||
Abbreviations: CI, confidence interval; CRNMB, clinically relevant nonmajor bleeding; DOAC, direct oral anticoagulant; MB, major bleeding.